IGF1 and prostate carcinoma: Interesting pre-clinical data also exist for the combination of insulin/IGF system inhibitors with other drugs, including the lipid modulator simvastatin in prostate cancer (161), the VEGF antibody bevacizumab in ovarian cancer (162), and methyl jasmonate in endometrial cancer (163).